- For Users
- For Industry
- News & Events
- Staff Directory
COVID-19 Information for Facility Users
Brookhaven Lab and NSLS-II Status
As of March 14, 2022, the Brookhaven Lab returned to Normal Operations mode. The Return-to-Site Guide provides information and direction on Brookhaven Lab's efforts to implement the COVID-19 Workplace Safety and Reentry Plan as staff and users return to the site.
The NSLS-II will be shut down from April 11 to May 13, 2022, for maintenance and upgrades. The user program for the May – August (2022-2) cycle will return to normal operations without quotas for onsite users.
BNL COVID-19 vaccination and face covering policies
Brookhaven Lab is located in Suffolk County, which is currently rated with a Community Level of LOW. While BNL remains in a CDC Community Level Designation of LOW, face coverings are optional on site. We also strongly encourage users to obtain a COVID-19 vaccination series to best protect themselves, their families, and those with whom they work.
It is important to remember that if Community Levels transition to MEDIUM or HIGH, COVID-19 controls at BNL will change (which could include, for example, providing evidence of vaccination status, face coverings, COVID-19 testing, etc.).
Social distancing and completion of online COVID-19 training are also no longer required. However, we do expect you to review and understand BNL's COVID-19 Return-to-Site guidelines by reading what's posted at https://www.bnl.gov/return/
Please continue to monitor your personal health status and be aware of symptoms that are not usual for you. If you have symptoms, please postpone your visit to Brookhaven until you feel well.
BNL Guest Appointments
A reminder that all users participating in experiments at NSLS-II must have a guest appointment. This includes on-site users, remote users, and users mailing samples to beamline staff. New users or users with expiring appointments should register online at the BNL Guest User Visitor (GUV) website.
All onsite users must complete the 5 required online training courses prior to coming onsite at BNL. For remote users, only 2 training courses are required. You can refer to the NSLS-II User Guide for details and access to all training modules.
To check the status of your training, go to the Training Website and select the "Training History" tab and ensure that all required courses are completed and not expired. If you were previously a remote user at NSLS-II and you're now coming onsite, note that the "Current Status" tab may not reflect the additional training courses needed for onsite access.
Arrival Onsite at BNL
For the first visit every cycle, on-site users must arrive at BNL Monday through Friday (and not a holiday) between 7:30 AM and 3 PM and check in at the Guest, User, Visitor (GUV) Center in Bldg 400 to confirm your appointment status and encode your NSLS-II access card. If you MUST arrive outside of these hours, please email the NSLS-II User Office at least 1 week in advance to make arrangements.
You will need a valid BNL appointment prior to reserving onsite housing. If you need to arrange onsite housing accommodations, please visit the BNL housing website.
COVID-19 Research Support at NSLS-II
The U.S. Department of Energy Basic Energy Sciences light sources want to ensure they are doing everything possible to enable research related to the Coronavirus pandemic. NSLS-II is offering a streamlined and expedited rapid access proposal process for groups that require beam time for projects directly related to COVID-19.
- CBMS: For structural biology projects, the Center for Biomolecular Structure team is supporting remote macromolecular crystallography experiments at the AMX and FMX beamlines as well as solution scattering experiments at the LiX beamline.
- LBMS: The new Laboratory for Biomolecular Structure is now open for cryo electron microscopy projects.
- DOE Resources: To see a complete list of DOE structural biology resources for COVID-19 research, visit this portal.
- Submit a Proposal: Follow this link to submit a proposal for any project related to COVID-19.